| Date:                         | 11/10/2021  |
|-------------------------------|---|
| Your Name:                    | Benjamin Vincent  |
| Manuscript Title:             | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition |
| Manuscript Number (if known): | 155523-JCI-CC-1   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None None  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | is .  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock<br>options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | None   |   |
| Plea | •  | e following statement to indicate your agreeme                                       |   |

| Date  | e:  |  | 11/10/2021  |   |
|---|---|--|---|---|
| Your Name:  |   |  | Chad Pecot  |   |
| Manuscript Title:   |   |  | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition                           |   |
| Mar   | nuscript Number (if k   | nown):   | 155523-JCI-CC-1   |   |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even it that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |   | ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if |   |   |
|   |   |  | entities with whom you have this hip or indicate none (add rows as needed)                              | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|   |   |  | Time frame: Since the initial planning  | of the work   |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | R01CA2   | one<br>215075, R01CA258451 and 1R41CA246848<br>ons of Richard and Fran Duley as well as<br>and Kay Mann | Click the tab key to add additional rows.   |
|   |   |  | Time frame: past 36 month   | s   |
| 2   | Grants or<br>contracts from<br>any entity (if not<br>indicated in item  | □ Nor  | ne  |   |
|   | #1 above).  |  |   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) | 9 |
|----|--|---|---|
| 4  | Consulting fees  | None None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |   |
| 6  | Payment for expert testimony   | None None   | ] |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   | ] |
| 8  | Patents planned,<br>issued or<br>pending   | □ None  Patents for RNA interference technology to target KRAS: 10,619,159 and 11,180,759   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   | ] |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   | ] |

|             |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-------------|---|---|---|
| 11          | Stock or stock<br>options   | Am the founder and have equity in EnFuego Therapeutics, Inc which is developing anti-KRAS targeting cancer therapeutics.  |   |
| 12          | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | None     Non |   |
| 13          | Other financial or<br>non-financial<br>interests  | None     Non |   |
|             |   | t to the following statement to indicate your agreeme   |   |
| $\boxtimes$ | I certify that I have   | answered every question and have not altered the wo   | rding of any of the questions on this form.   |

| Date:                         | 11/10/2021  |
|-------------------------------|---|
| Your Name:                    | Joel Parker   |
| Manuscript Title:             | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition |
| Manuscript Number (if known): | 155523-JCI-CC-1   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None None  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | hs  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock<br>options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | None   |   |
| Plea | •  | e following statement to indicate your agreeme                                       |   |

| Date:                         | 11/10/2021  |
|-------------------------------|---|
| Your Name:                    | Krishna Kanchi  |
| Manuscript Title:             | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition |
| Manuscript Number (if known): | 155523-JCI-CC-1   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |      | ies with whom you have this<br>indicate none (add rows as ne | eded)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|------|--|--------|---|
|   |   |      | Time frame: Since the initial pla                            | anning | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None |  |        | Click the tab key to add additional rows.   |
|   |   |      | Time frame: past 36  | month  | s   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None |  |        |   |
| 3 | Royalties or licenses   | None |  |        |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock<br>options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | None   |   |
| Plea | •  | e following statement to indicate your agreeme                                       |   |

| Date:                         | 11/10/2021  |
|-------------------------------|---|
| Your Name:                    | Leigh B Thorne  |
| Manuscript Title:             | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition |
| Manuscript Number (if known): | 155523-JCI-CC-1   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None None  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | hs  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock<br>options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | None   |   |
| Plea | •  | e following statement to indicate your agreeme                                       |   |

| Date:  |  | -          | 11/10/2021   |  |  |  |
|--|--|------------|--|--|--|--|
| Your Name:   |  |            | Mark Woodcock  |  |  |  |
| Manuscript Title:  |  |            | Rapid Idiosyncratic Mechanisms of Clini                                    | cal Resistance to KRAS G12C Inhibition   |  |  |
| Ma   | nuscript Number (if k  | nown):     | 155523-JCI-CC-1  |  |  |  |
| content of your manuscript. "Rela<br>affected by the content of the ma |  |            |  |  |  |  |
| epi  |  | nsion, you |  | example, if your manuscript pertains to the acturers of antihypertensive medication, even if |  |  |
|  | tem #1 below, report and the for disclosure is the   |            | ·  | ithout time limit. For all other items, the time   |  |  |
|  |  |            | entities with whom you have this hip or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)          |  |  |
|  |  |            | Time frame: Since the initial planning o                                   | of the work  |  |  |
|  |  |            |  |  |  |  |
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. |            | ted in part by the NIH 1T32CA211056.                                       | Click the tab key to add additional rows.  |  |  |
| 1  | present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for                                |            |  | Click the tab key to add additional rows.  |  |  |
| 2  | present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for                                |            | ted in part by the NIH 1T32CA211056.  Time frame: past 36 months           | Click the tab key to add additional rows.  |  |  |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None None  |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for expert testimony  | None □   |   |
| 7  | Support for attending meetings and/or travel  | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None □   |   |

|      |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock<br>options  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | None   |   |
| Plea | •  | e following statement to indicate your agreeme                                       |   |

| Date:  |   |            | 11/10/2021   |  |  |  |
|--|---|------------|--|--|--|--|
| You  | r Name:   |            | Salma Azam   |  |  |  |
| Manuscript Title:  |   |            | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition  |  |  |  |
| Mar  | nuscript Number (if k   | nown):     | 155523-JCI-CC-1  |  |  |  |
| content of your manuscript. "Rela<br>affected by the content of the ma |   |            | ated" means any relation with for-profit or no<br>nuscript. Disclosure represents a commitment<br>t about whether to list a relationship/activity, | /interest, it is preferable that you do so.  |  |  |
| epic   | ·   | nsion, you |  | example, if your manuscript pertains to the acturers of antihypertensive medication, even if |  |  |
|  | em #1 below, report and for disclosure is the   |            | ·  | ithout time limit. For all other items, the time   |  |  |
|  |   |            | l entities with whom you have this<br>ship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution)          |  |  |
|  |   |            | Time frame: Since the initial planning   | of the work  |  |  |
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | Suppor     | ted in part by an NIH 1R41CA246848 and C TRG award.  | Click the tab key to add additional rows.  |  |  |
|  |   |            | Time frame: past 36 month  | S  |  |  |
| 2  |   |            |  |  |  |  |
|  | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | □ No       | ne   |  |  |  |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for attending meetings and/or travel   | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None  Patents for RNA interference technology to target KRAS: 11,180,759  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|------|--|--|--|---|--|
| 11   | Stock or stock<br>options  |  | None   |   |  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services   |  | None   |   |  |
| 13   | Other financial or<br>non-financial<br>interests   |  | None   |   |  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |  |

| Date:                         | 11/10/2021  |
|-------------------------------|---|
| Your Name:                    | Yihsuan S. Tsai   |
| Manuscript Title:             | Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C Inhibition |
| Manuscript Number (if known): | 155523-JCI-CC-1   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None None  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | ns  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None None  |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4  | Consulting fees  | None None   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None   |
| 6  | Payment for expert testimony   | None  |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | None None   |
| 8  | Patents planned,<br>issued or<br>pending   | None  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | None None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None None   |

|      |  |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|------|--|--|--|---|--|
| 11   | Stock or stock<br>options  |  | None   |   |  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services   |  | None   |   |  |
| 13   | Other financial or<br>non-financial<br>interests   |  | None   |   |  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |  |